Pharmaceutical News

RSS

Maternal choline intake could essentially change fetal genetic expression into adulthood

Just as women are advised to get plenty of folic acid around the time of conception and throughout early pregnancy, new research suggests another very similar nutrient may one day deserve a spot on the obstetrician's list of recommendations.

24 Sep 2012

Topical NSAIDs as effective as oral NSAIDs for knee, hand arthritis

For those suffering from osteoarthritis of the knees or hands, applying topical non-steroidal anti-inflammatory drugs (NSAIDs) — in the form of creams, gels and patches — can bring weeks of pain relief, finds a new review by The Cochrane Library.

21 Sep 2012

FDA approves Mylan's ANDA for generic Antivert

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Meclizine Hydrochloride Tablets USP, 12.5 mg, 25 mg and 50 mg.

21 Sep 2012

Many states do not fully analyze data on fatal prescription painkiller overdoses

Prescription painkillers are responsible for more fatal overdoses in the United States than heroin and cocaine combined. And while most states have programs to curb abuse and addiction, a new report from Brandeis University shows that many states do not fully analyze the data they collect.

21 Sep 2012

Ciprofloxacin use is major contributor to MRSA spread in hospitals

The use of a commonly prescribed antibiotic is a major contributor to the spread of infection in hospitals by the 'superbug' MRSA, according to new research. The study also found that increasing measures to prevent infection - such as improved hygiene and hand washing - appeared to have only a small effect on reducing MRSA infection rates during the period studied.

21 Sep 2012

Cholera vaccine stockpiles could help save lives in future outbreaks

In a post in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Helen Matzger, a program officer in new vaccine delivery at the foundation, writes about outbreaks of cholera in Haiti, Sierra Leone, Guinea, and other areas, and says creating stockpiles of a recently WHO-approved cholera vaccine could help save lives in the future.

21 Sep 2012

Drug co. execs say cost-containment pressures undermine medical innovation

Pressure from governments to lower drug prices risks undermining medical innovation, Bayer AG's chief executive said on Wednesday, echoing complaints of other drug company executives. Speaking at the Boston College Chief Executives' Club, Marijn Dekkers said there was "tremendous pressure" on drugmakers to lower prices.

21 Sep 2012

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today reported milestone achievements advancing BiovaxID, Biovest's personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.

21 Sep 2012

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012

First phase of Global Fund-managed AMFm shows success in bringing malaria drugs to clinics

The Affordable Medicines Facility-malaria (AMFm) -- an innovative financing mechanism that subsidizes the cost of artemisinin-based combination therapies (ACTs) in order to expand access to the most effective treatment for malaria -- "brought more than 100 million doses of malaria drugs to clinics and pharmacies in 2011" and "also increased access to the top malaria medicines by 26 to 52 percent in six countries."

21 Sep 2012

Hypertonic solution effective in reducing inflammation

Research carried out at The University of Manchester has found further evidence that a simple solution, which is already used in IV drips, is an effective treatment for reducing inflammation.

From The University of Manchester 21 Sep 2012

TB Alliance, Sanofi partner to discover and develop novel compounds against tuberculosis

Sanofi and the Global Alliance for TB Drug Development announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB), a deadly infectious disease that resulted in almost 1.5 million deaths worldwide in 2010.

21 Sep 2012

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

21 Sep 2012

DNA barcoding effective in authenticating natural health products

DNA barcoding developed by University of Guelph researchers has proven up to 88 per cent effective in authenticating natural health products, according to a new U of G study.

20 Sep 2012

Institute for Translational Medicine and Therapeutics' 2012 symposium be held from Oct. 16-17

The Institute for Translational Medicine and Therapeutics' 7th Annual International Symposium (ITMAT) will be held October 16 and 17 at the Perelman School of Medicine, University of Pennsylvania.

20 Sep 2012

Study finds high levels of ESBL bacteria in Danish chicken meat

Nearly half of the samples from chicken meat imported into Denmark contain ESBL bacteria and for the first time the level is almost as high in Danish chicken meat. By contrast, the occurrence in Danish pigs has decreased significantly since farmers stopped using cephalosporins for pigs.

20 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Pharmaceutical News

Maternal choline intake could essentially change fetal genetic expression into adulthood

Topical NSAIDs as effective as oral NSAIDs for knee, hand arthritis

FDA approves Mylan's ANDA for generic Antivert

Many states do not fully analyze data on fatal prescription painkiller overdoses

Ciprofloxacin use is major contributor to MRSA spread in hospitals

Cholera vaccine stockpiles could help save lives in future outbreaks

Drug co. execs say cost-containment pressures undermine medical innovation

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

FDA approves Acton’s AEROSPAN sNDA to treat asthma

First phase of Global Fund-managed AMFm shows success in bringing malaria drugs to clinics

Hypertonic solution effective in reducing inflammation

TB Alliance, Sanofi partner to discover and develop novel compounds against tuberculosis

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

DNA barcoding effective in authenticating natural health products

Institute for Translational Medicine and Therapeutics' 2012 symposium be held from Oct. 16-17

Study finds high levels of ESBL bacteria in Danish chicken meat

Boehringer Ingelheim files MAA with EMA for afatinib approval

BMJ examines emergence of China as 'major new player' in global vaccine production

PCA inhibits multiple pathways involved in development of diabetic nephropathy

FDA Oncologic Drugs Advisory Committee to review Celgene’s pomalidomide NDA on Nov. 8

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News